Hansoh Pharma Announces Phase III Success of GLP-1R/GIPR Dual Agonist Olatorepatide with 19.3% Weight Loss at 48 Weeks

On March 7, Hansoh Pharma announced its first weight-loss drug, a glucagon-like peptide.Glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist Oleripetide (olatorepatide，HS-20094), the first Phase III clinical study (HS-20094-301) conducted in Chinese overweight or obese adult subjects, has achieved its primary endpoint.

This randomized, double-blind, placebo-controlled study was conducted across 33 clinical centers in China, enrolling a total of 604 adult subjects to evaluate the efficacy and safety of once-weekly oliceridine compared to placebo over a 48-week treatment period.

The study met the co-primary endpoints:

At 48 weeks of treatment, the reduction in body weight from baseline in the orleptin group showed a statistically significant difference compared to the placebo group, and the proportion of participants achieving a 5% weight reduction was significantly higher in the orleptin group.

After 48 weeks of Olerpeptide treatment, the average weight loss from baseline reached up to 19.3%, with the proportion of participants achieving a weight reduction of ≥5% reaching up to 97.2%.

The study showed that the oleyl peptide treatment group exhibited excellent gastrointestinal tolerance. Compared with the published Phase III trial data of GLP-1 related dual agonist drugs, the incidence of gastrointestinal adverse events and the discontinuation rate of treatment were lower.

Olepeptide is a once-weekly subcutaneous injectable GLP-1/GIP receptor dual agonist that modulates metabolic pathways associated with appetite control, glucose metabolism, and energy balance. Olepeptide is currently undergoing Phase III clinical trials in China for the treatment of obesity/overweight and type 2 diabetes. In June 2025, Hansoh Pharma signed a licensing agreement with Regeneron, granting it responsibility for the overseas development of Olepeptide.

Copyright © 2026 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. Medicine Cube assumes no responsibility for any loss incurred by any party due to the use of the content herein.